MA26869A1 - Synthese asymetrique de pregabaline - Google Patents

Synthese asymetrique de pregabaline

Info

Publication number
MA26869A1
MA26869A1 MA26738A MA26738A MA26869A1 MA 26869 A1 MA26869 A1 MA 26869A1 MA 26738 A MA26738 A MA 26738A MA 26738 A MA26738 A MA 26738A MA 26869 A1 MA26869 A1 MA 26869A1
Authority
MA
Morocco
Prior art keywords
pregabalin
pregabaline
asymmetric synthesis
synthesis
asymmetric
Prior art date
Application number
MA26738A
Other languages
English (en)
Inventor
Joseph Burk Mark
Simon Hoekstra Marvin
Arthur Mulhern Thomas
Andrew Ramsden James
Prakash Goel Om
Frederick Mich Thomas
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26874236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26869(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA26869A1 publication Critical patent/MA26869A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

DEPOSANT Société dite : WARNER-LAMBERT COMPANY REVENDICATION DE PRIORITES US 25 Janvier 2000 60/178,261 ?Synthèse asymétrique de prégabaline" L'invention propose un procédé pour la préparation d'acide (S)-(+)-3-(aminomethyl)-5-méthylhexanoïque (prégabaline) ou d'un de ses sels par une synthèse par hydrogénation asymétrique. La prégabaline est utile pour le traitement et la prévention d'attaques cérébrales, de la douleur et de troubles psychotiques. La présente invention propose également des intermédiaires utiles dans la production de la prégabaline.
MA26738A 2000-01-27 2002-07-23 Synthese asymetrique de pregabaline MA26869A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17835900P 2000-01-27 2000-01-27
US19042700P 2000-03-17 2000-03-17

Publications (1)

Publication Number Publication Date
MA26869A1 true MA26869A1 (fr) 2004-12-20

Family

ID=26874236

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26738A MA26869A1 (fr) 2000-01-27 2002-07-23 Synthese asymetrique de pregabaline

Country Status (50)

Country Link
US (1) US6891059B2 (fr)
EP (1) EP1250311B1 (fr)
JP (2) JP4235384B2 (fr)
KR (1) KR100549748B1 (fr)
CN (1) CN1210253C (fr)
AP (1) AP1438A (fr)
AR (1) AR028499A1 (fr)
AT (1) ATE261930T1 (fr)
AU (1) AU777046B2 (fr)
BG (1) BG65560B1 (fr)
BR (1) BRPI0107863B8 (fr)
CA (1) CA2396090C (fr)
CO (1) CO5251411A1 (fr)
CR (1) CR6703A (fr)
CU (1) CU23221A3 (fr)
CY (1) CY2004011I1 (fr)
CZ (1) CZ302838B6 (fr)
DE (1) DE60102356T2 (fr)
DK (1) DK1250311T3 (fr)
DZ (1) DZ3268A1 (fr)
EA (1) EA004934B1 (fr)
EE (1) EE05216B1 (fr)
EG (1) EG24138A (fr)
ES (1) ES2219493T3 (fr)
GE (1) GEP20043236B (fr)
HN (1) HN2001000010A (fr)
HR (1) HRP20020627B1 (fr)
HU (1) HU228815B1 (fr)
IL (2) IL150633A0 (fr)
IS (1) IS2038B (fr)
MA (1) MA26869A1 (fr)
ME (1) ME00921B (fr)
MX (1) MXPA02007307A (fr)
MY (1) MY127152A (fr)
NO (1) NO327958B1 (fr)
NZ (1) NZ519551A (fr)
OA (1) OA12167A (fr)
PA (1) PA8510501A1 (fr)
PE (1) PE20011063A1 (fr)
PL (1) PL203985B1 (fr)
PT (1) PT1250311E (fr)
RS (1) RS50257B (fr)
SI (1) SI1250311T1 (fr)
SK (1) SK287303B6 (fr)
SV (1) SV2002000295A (fr)
TN (1) TNSN01016A1 (fr)
TR (1) TR200400953T4 (fr)
TW (1) TWI288128B (fr)
UA (1) UA75584C2 (fr)
WO (1) WO2001055090A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (fr) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba et ses derives utilises pour le traitement de la douleur
TR200400953T4 (tr) * 2000-01-27 2004-07-21 Warner Lambert Company Pregabalinin asimetrik sentezi.
US6687187B2 (en) * 2000-08-11 2004-02-03 Phonak Ag Method for directional location and locating system
EP1543831A1 (fr) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Composition de pregabaline
PT1727620E (pt) * 2004-03-12 2007-11-05 Warner Lambert Co Ligandos de biofosfina c1-simétricos e a sua utilização na síntese assimétrica da pregabalina
UA82292C2 (uk) * 2004-04-14 2008-03-25 Пфайзер Продактс Инк. Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти)
CN1972904B (zh) * 2004-06-21 2011-02-02 沃尼尔·朗伯有限责任公司 普瑞巴林和相关化合物的制备
CN101160281A (zh) * 2005-04-06 2008-04-09 特瓦制药工业有限公司 结晶形态的普瑞巴林
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
MX2007012606A (es) * 2005-04-11 2008-01-11 Teva Pharma Proceso para elaborar (s)-pregabalina.
MX2007000525A (es) * 2005-05-10 2007-03-28 Teva Pharma Pregabalina libre de acido isobutilglutarico y un proceso para la preparacion de ella.
WO2006122258A1 (fr) 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Procede pour preparer de la pregabaline et des sels de celle-ci
ES2372700T3 (es) 2005-05-10 2012-01-25 Teva Pharmaceutical Industries Ltd Resolución óptica del ácido 3-carbamoilmetil-5-metil hexanoico.
US20060270871A1 (en) * 2005-05-30 2006-11-30 Khanduri Chandra H Polymorphic form i of pregabalin and processes for its preparation
CN100410242C (zh) * 2005-06-23 2008-08-13 江苏恩华药业股份有限公司 普瑞巴林中间体及其制备方法
WO2007035789A1 (fr) 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. Acides 3-carbamoylméthyl-5-méthylhexanoïques chiraux, intermédiaires clés pour la nouvelle synthèse de la (s)-prégabaline
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007127309A2 (fr) * 2006-04-24 2007-11-08 Teva Pharmaceutical Industries Ltd. Procede de synthese d'acide 3-isobutylglutarique
WO2007139933A2 (fr) 2006-05-24 2007-12-06 Teva Pharmaceutical Industries Ltd. Procédés pour la préparation d'acide r-(+)-3-(carbamoyl méthyl)-5-méthylhexanoïque et de sels de celui-ci
WO2007143113A2 (fr) * 2006-05-31 2007-12-13 Teva Pharmaceutical Industries Ltd. Utilisation de la résolution enzymatique pour la préparation d'intermédiaires de prégabaline
WO2007143152A2 (fr) * 2006-05-31 2007-12-13 Teva Pharmaceutical Industries Ltd. Préparation de (s)-prégabaline nitrile
EP1903027A1 (fr) * 2006-09-13 2008-03-26 Novartis AG Procédé de préparation de l' acide amino-4 butyrique ou de ses derivés et leur utilisation pour la préparation des inhibiteurs NEP
TW200846308A (en) 2007-03-22 2008-12-01 Teva Pharma Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
US8168828B2 (en) 2007-06-25 2012-05-01 Msn Laboratories, Limited Process for the preparation of pregabalin
KR100846419B1 (ko) * 2007-08-10 2008-07-15 한국과학기술원 프레가발린의 신규한 제조 방법
WO2009046309A2 (fr) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Prégabaline-4-éliminée, prégabaline-5-éliminée, leur utilisation en tant que marqueur de référence et standard et procédé de production de prégabaline contenant de faibles taux de ceux-ci
EP2053040A1 (fr) * 2007-10-26 2009-04-29 Chemo Ibérica, S.A. Intermédiaires de la Prégabaline et leurs procédés de préparation et Prégabaline
EP2225199A2 (fr) * 2007-12-18 2010-09-08 Watson Pharma Private Limited Procédé perfectionné pour la préparation de (s)-prégabaline
EP2222630A1 (fr) * 2007-12-26 2010-09-01 Generics (UK) Limited Procédés de préparation de la prégabaline
AU2008345851B2 (en) * 2008-01-10 2012-08-16 Sumitomo Chemical Company, Limited Method for producing cyclopropane carboxylic acid compound and intermediate therefor
EP2110372A1 (fr) 2008-04-16 2009-10-21 Chemo Ibérica, S.A. Intermédiaires pour la préparation de prégabaline et leur procédé de préparation
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
SI2294207T1 (sl) 2008-05-21 2013-01-31 Sandoz Ag Postopek za stereoselektivno encimatsko hidrolizo estra 5-metil-3-nitrometil-heksanojske kisline
WO2009158343A1 (fr) * 2008-06-23 2009-12-30 Teva Pharmaceutical Industries, Ltd. Synthèse enzymatique stéréosélective de l’ester (s) ou (r)-isobutylglutarique
WO2010070593A2 (fr) 2008-12-19 2010-06-24 Pfizer Ireland Pharmaceuticals Esters de malonate
CN101987826A (zh) * 2009-08-04 2011-03-23 铜陵凯顺生物科技有限公司 一种(3s)-3-氨甲基-5-甲基己酸的合成方法
WO2011141923A2 (fr) 2010-05-14 2011-11-17 Lupin Limited Synthèse améliorée d'un ester alkylique optiquement pur de l'acide (s) - 3-cyano-5-méthyl-hexanoïque, intermédiaire de la (s)-prégabaline
US8212072B2 (en) 2010-08-13 2012-07-03 Divi's Laboratories, Ltd. Process for the preparation of pregabalin
WO2012025861A1 (fr) * 2010-08-23 2012-03-01 Pfizer Manufacturing Ireland Procédé de préparation de dérivés d'acide (s)-3-cyano-5-méthylhexanoïque et de prégabaline
CN102464594B (zh) * 2010-11-17 2014-06-25 凯瑞斯德生化(苏州)有限公司 普瑞巴林的中间体化合物的制备方法
US9422230B2 (en) 2013-05-09 2016-08-23 Council Of Scientific And Industrial Research Process for the preparation of an anticonvulsant agent pregabalin hydrochloride
WO2016075082A1 (fr) 2014-11-10 2016-05-19 Sandoz Ag Amination réductrice stéréosélective d'aldéhydes alpha-chiraux au moyen d'ω-transaminases pour la synthèse de précurseurs de la prégabaline et du brivaracétam
WO2017019791A1 (fr) 2015-07-27 2017-02-02 Teva Pharmaceuticals International Gmbh Synthèse de (s)-prégabaline

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS588390B2 (ja) * 1978-05-23 1983-02-15 住友化学工業株式会社 光学活性ω↓−シアノ↓−α↓−アシルアミノ酸誘導体の製造法
US4939288A (en) * 1989-01-23 1990-07-03 Monsanto Company Method of preparing (R)-succinic acid derivatives
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5171892A (en) * 1991-07-02 1992-12-15 E. I. Du Pont De Nemours And Company Chiral phospholanes via chiral 1,4-diol cyclic sulfates
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5840965A (en) * 1996-06-24 1998-11-24 E. I. Du Pont De Nemours And Company Process for the production of purified telephthalic acid
EP0934061B3 (fr) * 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba et ses derives utilises pour le traitement de la douleur
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
EP1042270B1 (fr) 1997-12-17 2003-04-09 Chirotech Technology Limited Hydrogenation asymetrique
WO1999052852A1 (fr) 1998-04-09 1999-10-21 Chirotech Technology Limited Hydrogenation asymetrique
TR200400953T4 (tr) * 2000-01-27 2004-07-21 Warner Lambert Company Pregabalinin asimetrik sentezi.

Also Published As

Publication number Publication date
NO20023582D0 (no) 2002-07-26
BR0107863A (pt) 2002-11-05
IL150633A (en) 2009-08-03
NO20023582L (no) 2002-09-02
JP4886753B2 (ja) 2012-02-29
SK287303B6 (sk) 2010-06-07
CR6703A (es) 2003-06-24
CZ20022520A3 (cs) 2002-10-16
HU228815B1 (en) 2013-05-28
HRP20020627B1 (hr) 2011-01-31
EE200200403A (et) 2003-10-15
CZ302838B6 (cs) 2011-12-07
HUP0204307A2 (hu) 2003-06-28
YU56202A (sh) 2006-01-16
BR0107863B1 (pt) 2013-06-18
IS6430A (is) 2002-06-19
ES2219493T3 (es) 2004-12-01
CU23221A3 (es) 2007-07-20
AP2002002588A0 (en) 2002-09-30
EG24138A (en) 2008-08-06
US6891059B2 (en) 2005-05-10
CY2004011I1 (el) 2010-07-28
EA200200642A1 (ru) 2002-12-26
SV2002000295A (es) 2002-06-07
TWI288128B (en) 2007-10-11
AR028499A1 (es) 2003-05-14
DE60102356D1 (de) 2004-04-22
WO2001055090A1 (fr) 2001-08-02
RS50257B (sr) 2009-07-15
CO5251411A1 (es) 2003-02-28
NZ519551A (en) 2004-02-27
US20030212290A1 (en) 2003-11-13
JP2003520841A (ja) 2003-07-08
MY127152A (en) 2006-11-30
SK10782002A3 (sk) 2002-11-06
PA8510501A1 (es) 2002-02-21
PE20011063A1 (es) 2001-10-18
JP4235384B2 (ja) 2009-03-11
TNSN01016A1 (fr) 2005-11-10
EP1250311B1 (fr) 2004-03-17
IL150633A0 (en) 2003-02-12
CN1396905A (zh) 2003-02-12
KR100549748B1 (ko) 2006-02-08
BG106849A (en) 2003-03-31
OA12167A (en) 2006-05-08
HN2001000010A (es) 2001-06-13
AP1438A (en) 2005-05-23
CA2396090A1 (fr) 2001-08-02
PT1250311E (pt) 2004-07-30
EA004934B1 (ru) 2004-10-28
EE05216B1 (et) 2009-10-15
SI1250311T1 (en) 2004-10-31
UA75584C2 (uk) 2006-05-15
TR200400953T4 (tr) 2004-07-21
HUP0204307A3 (en) 2003-07-28
IS2038B (is) 2005-08-15
ME00921B (me) 2012-06-20
KR20020073187A (ko) 2002-09-19
MXPA02007307A (es) 2002-11-29
DZ3268A1 (fr) 2001-08-02
NO327958B1 (no) 2009-10-26
JP2009073841A (ja) 2009-04-09
CA2396090C (fr) 2006-01-10
AU777046B2 (en) 2004-09-30
AU2213801A (en) 2001-08-07
DK1250311T3 (da) 2004-08-16
HRP20020627A2 (en) 2004-08-31
BG65560B1 (bg) 2008-12-30
CN1210253C (zh) 2005-07-13
DE60102356T2 (de) 2005-02-17
EP1250311A1 (fr) 2002-10-23
PL357077A1 (en) 2004-07-12
ATE261930T1 (de) 2004-04-15
PL203985B1 (pl) 2009-11-30
BRPI0107863B8 (pt) 2017-04-25
GEP20043236B (en) 2004-05-25

Similar Documents

Publication Publication Date Title
TNSN01016A1 (fr) Procede pour la synthese asymetrique de pregabaline
CN1171866C (zh) 芳氧基芳基磺酰氨基异羟肟酸衍生物
NO20004432L (no) Glysintransportinhibitorer
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
EP0863755A4 (fr) Diamines antithrombotiques
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
TNSN98036A1 (fr) Derives d'acide hexanoique nouveaux
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27472A1 (fr) Acetyle 2-hydroxy-1, 3 diaminoalcanes
CA2322558A1 (fr) Composes d'acide amines soumis a une contrainte de conformation et presentant une affinite pour la sous-unite alpha 2 delta d'un canal calcique
WO2003103663A3 (fr) Pyrrolines substituees en tant qu'inhibiteurs de kinase
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99147A1 (fr) Procede d'emulsification
MA27676A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
DK0888285T3 (da) Nye broforbundne cycliske aminosyrer som farmaceutiske midler
JO2216B1 (en) 5 chloro-3 (4-methane sulfonyl phenyl) -6-methyl- (2.3)
TNSN96153A1 (fr) Procedes et intermediaires pour la preparation de 1-benzyl-4 ((5,6 -dimethoxy-1-indanone)-2- yl) methylpiperidine.
TNSN01052A1 (fr) Metabolites du (-) - cis - 6 - phenyl - 5 - [4 -( 2-pyrrolidine -1- yl - ethoxy) - phenyl] - 5,6,7,8- tetrahydro - naphtalene - 2 - ol et compositions les contenant
BE1002375A3 (fr) Matieres biologiques, procede pour la production de matieres biologiques et pour l'utilisation de telles matieres en therapie.
TNSN06314A1 (fr) Sulfonamides destines au traitement de troubles neurodegeneratifs
BR9607443A (pt) Composto de 4-aminotetraidrobenzisoxazol ou-isatiazol composição farmacêutica e utilização do composto
TNSN99054A1 (fr) Procede pour alkyler des sulfonamides a encombrement sterique
MA24670A1 (fr) Methode pour la preparation d'acides 4-phenyl-4-cyano-cyclohexanoiques substitues
TNSN00142A1 (fr) Complexe d'eletriptan et d'une sulfobutylether- betacyclodextrine, procede pour sa preparation et compositions pharmaceutiques les contenant.